1 results match your criteria: "VA 3Icahn School of Medicine at Mount Sinai[Affiliation]"
Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial.
Menopause
November 2016
1Department of Obstetrics and Gynecology, George Washington University School of Medicine, Washington, DC 2Department of Health & Sciences, Stratford University, Falls Church, VA 3Icahn School of Medicine at Mount Sinai, New York, NY.
Objective: Assess effects of once-daily, extended-release oxybutynin chloride on frequency and severity of vasomotor symptoms in healthy, postmenopausal symptomatic women.
Methods: A 12-week, multicenter, double-blind, placebo-controlled, phase 2 clinical trial randomized naturally postmenopausal women experiencing at least seven moderate-to-severe vasomotor symptoms daily to oxybutynin 15 mg once daily (n = 73) or placebo (n = 75). Co-primary outcomes were the change from baseline to week 12 in the frequency and severity of moderate-to-severe vasomotor symptoms.